Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Rani Therapeutics Holdings Inc Cl A (RANI)

Rani Therapeutics Holdings Inc Cl A (RANI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 329,030
  • Shares Outstanding, K 50,157
  • Annual Sales, $ 0 K
  • Annual Income, $ -33,970 K
  • 60-Month Beta 0.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 13.19
Trade RANI with:

Options Overview Details

View History
  • Implied Volatility 222.82% ( +26.26%)
  • Historical Volatility 138.93%
  • IV Percentile 79%
  • IV Rank 21.40%
  • IV High 981.12% on 11/15/23
  • IV Low 16.41% on 05/11/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 285
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 466
  • Open Int (30-Day) 1,146

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.23
  • Number of Estimates 1
  • High Estimate -0.23
  • Low Estimate -0.23
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +30.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.85 +130.18%
on 03/26/24
8.75 -25.03%
on 04/17/24
+3.33 (+102.78%)
since 03/25/24
3-Month
2.85 +130.18%
on 03/26/24
8.75 -25.03%
on 04/17/24
+2.90 (+79.23%)
since 01/25/24
52-Week
1.82 +260.44%
on 11/02/23
8.75 -25.03%
on 04/17/24
+1.97 (+42.92%)
since 04/25/23

Most Recent Stories

More News
Rani Therapeutics Holdings, Inc. (RANI) Reports Q3 Loss, Lags Revenue Estimates

Rani Therapeutics Holdings, Inc. (RANI) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

RANI : 6.56 (-6.15%)
VRDN : 12.70 (-2.53%)
Here's Why Rani Therapeutics Holdings, Inc. (RANI) Is a Great 'Buy the Bottom' Stock Now

Rani Therapeutics Holdings, Inc. (RANI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions...

RANI : 6.56 (-6.15%)
Rani Therapeutics Announces Proposed Public Offering of Class A Common Stock

SAN JOSE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”) (Nasdaq: RANI), a clinical-stage...

RANI : 6.56 (-6.15%)
Rani Therapeutics Reports Second Quarter 2022 Financial Results; Provides Corporate Update

- Announced positive topline Phase 1 results of RT-102 for the treatment of osteoporosis - - Anticipate initiating an additional Phase 1 clinical trial in...

RANI : 6.56 (-6.15%)
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis

- RT-102 was generally well-tolerated, with no RaniPill™-related adverse events - - Bioavailability of PTH delivered via the RaniPill was found to be...

RANI : 6.56 (-6.15%)
Rani Therapeutics Enters into $45 Million Loan Agreement to Support Ongoing RaniPill® Platform Advancement and Clinical Pipeline Development

Extends Rani’s projected cash runway into mid-2024...

RANI : 6.56 (-6.15%)
Axsome (AXSM) Hurt by Regulatory Setbacks: Will It Recover?

Axsome's (AXSM) extension of the review period for AXS-05 NDA and CRL for AXS-07 NDA hurt prospects. However, recent positive updates on AXS-05 are driving positive sentiments.

JAZZ : 107.43 (-0.82%)
AXSM : 71.52 (+0.49%)
SESN : 12.5760 (+7.29%)
RANI : 6.56 (-6.15%)
Rani Therapeutics Reports First Quarter 2022 Financial Results; Provides Corporate Update

- Initiated a Phase 1 clinical trial of RT-102 for the treatment of osteoporosis – - Unveiled the high-capacity RaniPill™ HC, capable of delivering...

RANI : 6.56 (-6.15%)
Rani Therapeutics Holdings Enters Oversold Territory (RANI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

RANI : 6.56 (-6.15%)
Rani Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

SAN JOSE, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage...

RANI : 6.56 (-6.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Rani Therapeutics Holdings Inc. is a clinical stage biotherapeutics company. It focused on advancing technologies to enable the development of orally administered biologics. Rani Therapeutics Holdings Inc. is based in SAN JOSE, Calif.

See More

Key Turning Points

3rd Resistance Point 8.10
2nd Resistance Point 7.66
1st Resistance Point 7.11
Last Price 6.56
1st Support Level 6.12
2nd Support Level 5.69
3rd Support Level 5.14

See More

52-Week High 8.75
Last Price 6.56
Fibonacci 61.8% 6.10
Fibonacci 50% 5.28
Fibonacci 38.2% 4.47
52-Week Low 1.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar